NCT04227938View on ClinicalTrials.gov

ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

May 11, 2020

Primary Completion Date

May 21, 2020

Study Completion Date

May 21, 2020

Conditions
Graft Vs Host Disease
Interventions
DRUG

ALPN-101

A single dose of ALPN-101 will be administered via intravenous infusion.

Trial Locations (4)

33136

University of Miami, Miami

37203

Sarah Cannon Center for Blood Cancer, Nashville

66160

University of Kansas Hospital, Kansas City

78704

St. David's South Austin medical Center, Austin

Sponsors
All Listed Sponsors
lead

Alpine Immune Sciences, Inc.

INDUSTRY

NCT04227938 - ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD | Biotech Hunter | Biotech Hunter